about
Stress-induced nuclear bodies are sites of accumulation of pre-mRNA processing factorsHuman proliferating cell nuclear antigen, poly(ADP-ribose) polymerase-1, and p21waf1/cip1. A dynamic exchange of partnersCaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia.KCNJ2 mutation in short QT syndrome 3 results in atrial fibrillation and ventricular proarrhythmiaAdeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia.Human chromosomes 9, 12, and 15 contain the nucleation sites of stress-induced nuclear bodiesAllele-Specific Silencing of Mutant mRNA Rescues Ultrastructural and Arrhythmic Phenotype in Mice Carriers of the R4496C Mutation in the Ryanodine Receptor Gene (RYR2).Transcriptional activation of a constitutive heterochromatic domain of the human genome in response to heat shock.Single delivery of an adeno-associated viral construct to transfer the CASQ2 gene to knock-in mice affected by catecholaminergic polymorphic ventricular tachycardia is able to cure the disease from birth to advanced age.DNA ligase I is dephosphorylated during the execution step of etoposide-induced apoptosis.Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity.Evidence of poly(ADP-ribosylation) in the cockroach Periplaneta americana.The AMPK-activator AICAR in thyroid cancer: effects on CXCL8 secretion and on CXCL8-induced neoplastic cell migration.Subclinical abnormalities in sarcoplasmic reticulum Ca(2+) release promote eccentric myocardial remodeling and pump failure death in response to pressure overload.The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors
P50
Q24555114-88962381-1434-489F-8AA0-D05CD82D9602Q28202875-A82D89D1-BB7B-4452-BF2D-C83CFE0ADCC1Q30557177-3824681E-825B-44E0-B91F-BC442473DA19Q36692867-5757AB36-3911-4C95-A61E-450AD22AB0B6Q37465870-9BE6A830-020F-41B4-BAB5-255011D8FA4EQ39617231-51076AF9-A234-4CA2-9E98-322A1A6C1ACDQ40157909-F400424D-2AC2-498F-80E3-C192222390FCQ40509160-7DC8F68F-B458-4D9E-B7DF-48DC1F6D5A57Q42215203-FFACB54A-759F-49C7-8E84-226013BDDB6EQ43861761-E3DC3DCB-587C-4996-8BC0-1973A6D5C082Q44073503-16517F76-46D8-4A99-8FC8-BF66D6575D5BQ52582633-89BC76E0-F720-412B-8C67-52895F6CA7D2Q52652690-8BB7BBDF-1D67-4213-8431-7151D0A2C911Q53079712-63E73CA9-4F44-49AF-ADCC-AC7E055835F3Q64100405-455E95A8-F195-453D-83D3-90D2C3A1E1CB
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marco Denegri
@ast
Marco Denegri
@en
Marco Denegri
@es
Marco Denegri
@nl
type
label
Marco Denegri
@ast
Marco Denegri
@en
Marco Denegri
@es
Marco Denegri
@nl
prefLabel
Marco Denegri
@ast
Marco Denegri
@en
Marco Denegri
@es
Marco Denegri
@nl
P106
P31
P496
0000-0003-1665-0625